Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

A modestly-priced acquisition of an NK cell platform company in spring 2019 set up Kiadis for a premium takeout by its partner Sanofi, even after the Dutch biotech discontinued its lead T cell program late last year.

Sanofi (Euronext:SAN; NASDAQ:SNY) said it intends to pay €308 million ($358.3 million) to acquire Kiadis Pharma N.V. (Euronext:KDS). The deal values Kiadis at €5.45 per share, a 273% premium over its closing price Friday at €1.46...